trending Market Intelligence /marketintelligence/en/news-insights/trending/lzrkt7yn5mx5t8htmanpxg2 content esgSubNav
In This List

Emergent BioSolutions completes acquisition of Adapt Pharma

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Emergent BioSolutions completes acquisition of Adapt Pharma

Emergent BioSolutions Inc. completed the acquisition of Adapt Pharma Ltd., maker of emergency opioid overdose treatment Narcan.

Narcan is a U.S. Food and Drug Administration-approved nasal spray version of naloxone, used to reverse opioid overdose.

The deal has a total consideration of up to $735 million. Gaithersburg, Md.-based Emergent paid $635 million at closing, comprising $60 million in Emergent common stock and $575 million in cash. Up to $100 million in cash will be paid out based on sales milestones through 2022.

Emergent will fund the deal through a combination of cash-on-hand and new $1.05 billion syndicated senior secured credit facilities.

About 50 employees — located in the U.S., Canada and Ireland — of Dublin-based Adapt Pharma will now join Emergent.

Emergent makes drugs for biohazards and public health threats including anthrax and botulism.